Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy
Acta Pharmaceutica Sinica B · 2023-12 · 13 (12) · 5048-5059
DOI: 10.1016/j.apsb.2023.07.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-12. Verfasst von Xiaodi Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Laboratory of Ultrasound Imaging and Drug, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Sichuan University West China Hospital.
Abstract (Originalsprache)
T cell infiltration and proliferation in tumor tissues are the main factors that significantly affect the therapeutic outcomes of cancer immunotherapy. Emerging evidence has shown that interferon-gamma (IFNγ) could enhance CXCL9 secretion from macrophages to recruit T cells, but Siglec15 expressed on TAMs can attenuate T cell proliferation. Therefore, targeted regulation of macrophage function could be a promising strategy to enhance cancer immunotherapy via concurrently promoting the infiltration and proliferation of T cells in tumor tissues. We herein developed reduction-responsive nanoparticles (NPs) made with poly (disulfide amide) (PDSA) and lipid-poly (ethylene glycol) (lipid-PEG) for systemic delivery of Siglec15 siRNA (siSiglec15) and IFNγ for enhanced cancer immunotherapy. After intravenous administration, these cargo-loaded could highly accumulate in the tumor tissues and be efficiently internalized by tumor-associated macrophages (TAMs). With the highly concentrated glutathione (GSH) in the cytoplasm to destroy the nanostructure, the loaded IFNγ and siSiglec15 could be rapidly released, which could respectively repolarize macrophage phenotype to enhance CXCL9 secretion for T cell infiltration and silence Siglec15 expression to promote T cell proliferation, leading to significant inhibition of hepatocellular carcinoma (HCC) growth when combining with the immune checkpoint inhibitor. The strategy developed herein could be used as an effective tool to enhance cancer immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound, Laboratory of Ultrasound Imaging and Drug, West China Hospital, Sichuan University, Chengdu 610041, China.
- Department of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
- Department of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang 524045, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Sichuan University West China Hospital
Zitieren
APA
Liu, X., Zhang, Q., Liang, Y., Xiong, S., Cai, Y., Cao, J., Xu, Y., Xu, X., Wu, Y., Lu, Q., Xu, X., & Luo, B. (2023). Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy. Acta Pharmaceutica Sinica B, 13(12), 5048-5059. https://doi.org/10.1016/j.apsb.2023.07.012
Vancouver
Liu X, Zhang Q, Liang Y, Xiong S, Cai Y, Cao J, et al. Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy. Acta Pharmaceutica Sinica B. 2023;13(12):5048-5059. doi:10.1016/j.apsb.2023.07.012
BibTeX
@article{Liu2023,
author = {Liu, Xiaodi and Zhang, Qi and Liang, Yixia and Xiong, Shiyu and Cai, Yan and Cao, Jincheng and Xu, Yanni and Xu, Xiaolin and Wu, Ye and Lu, Qiang and Xu, Xiaoding and Luo, Baoming},
title = {Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {12},
pages = {5048--5059},
doi = {10.1016/j.apsb.2023.07.012}
}
EUVIMED